< Back

PolyPid to Present at the Barclays Global Healthcare Conference

March 1, 2022 at 7:00 AM EST

PETACH TIKVA, Israel, March 01, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a Phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today announced that it will present at the Barclays Global Healthcare Conference, which is being held in Miami, Florida, on March 15-17, 2022.

Barclays Global Investor Conference:

Presentation Date:  Wednesday, March 16, 2022
Presentation Time: 9:00 AM Eastern Time
Webcast: https://barclays.webcasts.com/starthere.jsp?ei=1533028&tp_key=1d6b22fa07&tp_special=8

Following the live presentation, a replay of the presentation will be available under the Investor section of PolyPid’s website at https://investors.polypid.com/events-and-presentations/events and archived for 30 days thereafter. Investors interested in meeting with PolyPid during the conference should contact their Barclays representative.

About PolyPid
PolyPid Ltd. (Nasdaq: PYPD), is a phase 3 biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics. PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with medications, enables precise delivery of drugs at effective release rates, over pre-determined durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX100 is in Phase 3 clinical trials for the prevention of abdominal and sternal surgical site infections (SSIs).
For additional Company information, please visit polypid.com and follow us on Twitter and LinkedIn.

References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. PolyPid is not responsible for the contents of third-party websites.

PolyPid, Ltd. 
Dikla Czaczkes Akselbrad
Tel: +972-747195700

Bob Yedid
LifeSci Advisors

Media Contact:
Nechama Feuerstein

Primary Logo

Source: PolyPid Ltd.


PolyPid’s PLEX targeted drug delivery platform enables localized, controlled, continuous release of medication over prolonged periods of time for better patient outcomes.

Read More >


Provides safe and effective local antibiotic protection against SSI (surgical Site Infection) at the needed tissues or organs by administration during surgical procedures.

Read More >


Comprised of antibiotic eluting ß tri-calcium phosphate (ßTCP) granules, designed for bone related infections applications.

Read More >